𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease

✍ Scribed by M. Yamamoto; M. Yokochi; S. Kuno; Y. Hattori; Y. Tsukamoto; H. Narabayashi; H. Tohgi; Y. Mizuno; H. Kowa; N. Yanagisawa; I. Kanazawa

Publisher
Springer
Year
1997
Tongue
English
Weight
517 KB
Volume
104
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphism of catechol-O-methy
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease
✍ Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract We explored the potential effect of catechol‐__O__‐methyltransferase (COMT) genetic polymorphism on the pharmacokinetics and pharmacodynamics of a standard oral dose of levodopa in patients with Parkinson's disease (PD). We prospectively collected blood samples for COMT genotyping from

Effect of entacapone, a COMT inhibitor,
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari

Randomized trial of tolcapone versus per
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),